Abstract

The retention using selective hooks (RUSH) system allows to retain a target protein fused to green fluorescent protein (GFP) and a streptavidin-binding peptide (SBP) due to the interaction with a molar excess of streptavidin molecules (“hooks”) targeted to selected subcellular compartments. Supplementation of biotin competitively disrupts the interaction between the SBP moiety and streptavidin, liberating the chimeric target protein from its hooks, while addition of avidin causes the removal of biotin from the system and reestablishes the interaction. Based on this principle, we engineered two chimeric proteins involved in autophagy, namely microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B, best known as LC3) and sequestosome-1 (SQSTM1, best known as p62) to move them as SBP–GFP–LC3 and p62–SBP–GFP at will between the cytosol and two different organelles, the endoplasmic reticulum (ER) and the Golgi apparatus. Although both proteins were functional in thus far that SBP–GFP–LC3 and p62–SBP–GFP could recruit their endogenous binding partners, p62 and LC3, respectively, their enforced relocation to the ER or Golgi failed to induce organelle-specific autophagy. Hence, artificial tethering of LC3 or p62 to the surface of the ER and the Golgi is not sufficient to trigger autophagy.

Details

Title
Artificial tethering of LC3 or p62 to organelles is not sufficient to trigger autophagy
Author
Loos, Friedemann 1 ; Xie, Wei 1 ; Sica, Valentina 1 ; Bravo-San Pedro, José Manuel 1 ; Souquère, Sylvie 2 ; Pierron, Gérard 3 ; Lachkar, Sylvie 1 ; Sauvat, Allan 1 ; Petrazzuolo, Adriana 1 ; Jimenez, Ana Joaquina 4 ; Perez, Franck 4   VIAFID ORCID Logo  ; Maiuri, Maria Chiara 1 ; Kepp, Oliver 1   VIAFID ORCID Logo  ; Kroemer, Guido 5 

 Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Center, Villejuif, France; Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Institut National de la Santé et de la Recherche Médicale, UMR1138, Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Villejuif, France 
 AMMICA UMS-3655, Gustave Roussy Cancer Center, Villejuif, France 
 CNRS, Villejuif, France 
 Institut Curie, PSL Research University, CNRS UMR144, Paris, France 
 Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Center, Villejuif, France; Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Institut National de la Santé et de la Recherche Médicale, UMR1138, Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Villejuif, France; Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou, China; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden 
Pages
1-10
Publication year
2019
Publication date
Oct 2019
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2303724475
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.